TRAWS PHARMA, INC.
TRAW evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $8.1M
- Lead Asset:
- narazaciclib (Phase 1)
What it means
What to watch
Prepared research question
What matters most for TRAW—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRAW
TRAWS PHARMA, INC. is a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases and oncology, with four clinical programs including tivoxavir marboxil, ratutrelvir, narazaciclib, and rigosertib.
Key risk: Cash runway concern
BioSniper Score
Based on 4 of 6 signals
Market Cap
$8.1M
Cash Runway
—
Lead Asset
narazaciclib (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 11 clinical trials for TRAWS PHARMA, INC..
TRAWS PHARMA, INC. is a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases and oncology, with four clinical programs including tivoxavir marboxil, ratutrelvir, narazaciclib, and rigosertib.
- TRAWS PHARMA is a clinical-stage biopharmaceutical company focused on respiratory viral diseases and oncology [sec · filed 2026-07-01].
- The company has four clinical programs: tivoxavir marboxil (bird flu/seasonal influenza), ratutrelvir (COVID-19), narazaciclib (oncology), and rigosertib (oncology) [sec · filed 2026-07-01].
- Narazaciclib is a multi-targeted kinase inhibitor in Phase 1 for solid tumors and hematological malignancies, with a partnership for development in greater China [pipeline].
- The company reported a net loss of -$3.1M as of 2026-06-30 [latest reported financials].
- TRAWS PHARMA has expressed substantial doubt about its ability to continue as a going concern within one year from its latest financial statements [sec_mda · as of 2026-05-15].
What works
- The company has four clinical-stage programs spanning both respiratory viral diseases and oncology, diversifying its pipeline [sec · filed 2026-07-01].
- Narazaciclib is partnered with HanX Biopharmaceuticals for development in greater China, providing potential milestone and royalty payments [pipeline].
- Tivoxavir marboxil is designed as a single-dose treatment for bird flu and seasonal influenza, addressing a critical public health need [sec · filed 2026-07-01].
What to weigh
- The company has not achieved profitability since inception and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-04-15].
- TRAWS PHARMA has stated it does not have sufficient cash to support operations for more than one year from its latest financial statements, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-15].
- The company faces significant financing risk, noting that if additional funds are not obtained, it may need to scale back operations [sec_mda · as of 2026-08-14].
- Any future financing through collaborations may require relinquishing valuable rights to technologies or product candidates [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Narazaciclib is a multi-targeted kinase inhibitor in Phase 1.
“Pipeline Candidate: narazaciclib Generic Name: Narazaciclib Indication: solid tumors and hematological malignancies Phase: Phase 1 Mechanism of Action: multi-targeted kinase inhibitor targeting multiple cyclin-dependent kinases ("CDK's"), AMP-activated protein kinase ("AMPK") related protein kinase 5 ("ARK5"), and colony-stimulating factor 1 receptor ("CSF1R")”
Catalyst timeline
- 2024-04-15 · Phase 1 start for 83-0060 (healthy volunteers) — First-in-human study of orally administered 83-0060 evaluating safety, tolerability, and pharmacokinetics.
- 2024-08-13 · Phase 1 start for TRX-100 (healthy volunteers) — Dose escalation study of orally administered TRX-100 evaluating safety, tolerability, and pharmacokinetics.
- 2025-09-16 · Phase 2a start for ratutrelvir (COVID-19) — Open-label, randomized study evaluating safety and efficacy of ratutrelvir plus standard of care in non-hospitalized symptomatic adults.
Risks & what to watch (4)›
Key risks
- Cash runway concern — Company states it does not have sufficient cash to operate beyond one year from latest financial statements [sec_mda · as of 2026-05-15].
- Going concern risk — Substantial doubt raised about ability to continue as a going concern within one year [sec_mda · as of 2026-05-15].
- Financing dependency — Future operations depend on obtaining additional financing; may need to scale back if not obtained [sec_mda · as of 2026-08-14].
- Potential loss of rights — Future collaborations may require relinquishing valuable rights to technologies or product candidates [sec_mda · as of 2026-08-14].
What to watch
- Ability to secure additional financing to support ongoing operations and clinical trials [sec_mda · as of 2026-08-14].
- Progress of Phase 2a study of ratutrelvir for COVID-19, which started in September 2025 [catalyst].
- Data analysis from the narazaciclib Phase 1 study in healthy volunteers, which started in April 2024 [catalyst].
- Potential new partnerships for narazaciclib or other pipeline assets [sec_mda · as of 2026-04-15].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run TRAWS PHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TRAWS PHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$3M
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for TRAWS PHARMA, INC.?
TRAWS PHARMA, INC. is a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases and oncology, with four clinical programs including tivoxavir marboxil, ratutrelvir, narazaciclib, and rigosertib.
What is TRAWS PHARMA, INC.'s lead drug candidate?
TRAWS PHARMA, INC.'s most advanced tracked candidate is narazaciclib (Phase 1) for solid tumors and hematological malignancies.
Who is the CEO of TRAWS PHARMA, INC.?
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. is the chief executive officer of TRAWS PHARMA, INC. (TRAW).
Where is TRAWS PHARMA, INC. headquartered?
TRAWS PHARMA, INC. (TRAW) is headquartered in Newtown, PA, United States.
What therapeutic areas does TRAWS PHARMA, INC. focus on?
TRAWS PHARMA, INC. develops therapies across Oncology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.